Neoadjuvant Chemotherapy for Clinical Stage II and III Thoracic Esophageal Squamous Cell Carcinoma with Curative EsophagectomyReport as inadecuate




Neoadjuvant Chemotherapy for Clinical Stage II and III Thoracic Esophageal Squamous Cell Carcinoma with Curative Esophagectomy - Download this document for free, or read online. Document in PDF available to download.

Esophageal squamous cell carcinoma ESCC is a gastrointestinal carcinomawith a poor prognosis. To improve the survival of patients with this disease, neoadjuvantchemotherapy NAC has been introduced. However, the survival benefits of NAC orthe correlation between NAC and postoperative complications have not been well considered.In the present study, we retrospectively investigated the clinicopathological effectivenessof NAC in patients with clinical stage II and III thoracic ESCC. This retrospectivestudy enrolled 63 patients with clinical stage II and III thoracic ESCC, who underwentresection of the thoracic esophagus and three-field lymph node dissection betweenJanuary 2007 and December 2013. NAC with cisplatin plus 5-fluorouracil 5-FU wasintroduced in 38 patients. NAC did not correlate with the occurrence of postoperativecomplications. The 5-year disease-free survival DFS rate of the 38 patients withNAC 41.6% was similar to that for the 25 patients who did not receive NAC 38.1%; P = 0.784. However, we found that theDFS of 17 patients with histopathological Grade 2 and 3 tumors who received NAC5-year DFS rate: 58.1% was significantly higher than that of 21 patients withlow histopathological grade tumors who received NAC 5-year DFS rate: 28.6%, orthan that of the 25 patients who did not receive NAC 38.1%. Moreover, we foundthat the effectiveness of NAC assessed macroscopically did not correlate with theeffectiveness of NAC assessed microscopically. These findings may indicate thatpreoperative estimation of NAC effectiveness is important in avoiding unnecessaryadverse drug effects caused by NAC, and in prolonging the survival of patients withthoracic ESCC.

KEYWORDS

Esophageal Squamous Cell Carcinoma, Histopathological Grade, Neoadjuvant Chemotherapy, Prognosis

Cite this paper

Ikeguchi, M. , Kohno, Y. , Kihara, K. , Suzuki, K. , Endo, K. , Nakamura, S. , Sawada, T. , Shimizu, T. , Matsunaga, T. , Fukumoto, Y. and Saito, H. 2015 Neoadjuvant Chemotherapy for Clinical Stage II and III Thoracic Esophageal Squamous Cell Carcinoma with Curative Esophagectomy. Journal of Cancer Therapy, 6, 1207-1213. doi: 10.4236-jct.2015.615131.





Author: Masahide Ikeguchi1*, Yusuke Kohno1, Kyoichi Kihara1, Kazunori Suzuki1, Kanenori Endo1, Seiichi Nakamura1, Takashi Sawada1, Tetsu

Source: http://www.scirp.org/



DOWNLOAD PDF




Related documents